# Philip M Farrell

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 101 papers | 6,236 citations | 38 h-index | 78 g-index |
| 111 ext. papers | 7,373 ext. citations | 4.5 avg, IF | 5.51 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 101 | Newborn screening alone insufficient to improve pulmonary outcomes for cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 492-498 | 4.1 | 4 |
| 100 | Challenging the dogma of the healthy heterozygote: Implications for newborn screening policies and practices. *Molecular Genetics and Metabolism*, **2021**, 134, 8-19 | 3.7 | 2 |
| 99 | Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study. *Pediatric Pulmonology*, **2021**, 56, 3758-3767 | 3.5 | 3 |
| 98 | Experience with Parent Follow-Up for Communication Outcomes after Newborn Screening Identifies Carrier Status. *Journal of Pediatrics*, **2020**, 224, 37-43.e2 | 3.6 | 6 |
| 97 | Applying whole-genome sequencing in relation to phenotype and outcomes in siblings with cystic fibrosis. *Journal of Physical Education and Sports Management*, **2020**, 6, | 2.8 | 3 |
| 96 | The Impact of the CFTR Gene Discovery on Cystic Fibrosis Diagnosis, Counseling, and Preventive Therapy. *Genes*, **2020**, 11, | 4.2 | 7 |
| 95 | Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. *Pediatric Pulmonology*, **2020**, 55, 918-928 | 3.5 | 15 |
| 94 | Setting a new standard in cystic fibrosis newborn screening illustrates controversial issues as new data emerge. *European Journal of Human Genetics*, **2020**, 28, 1305-1306 | 5.3 | |
| 93 | Newborn Screening for CF across the Globe-?. *International Journal of Neonatal Screening*, **2020**, 6, 18 | 2.6 | 24 |
| 92 | Vulnerable Child Syndrome and Newborn Screening Carrier Results for Cystic Fibrosis or Sickle Cell. *Journal of Pediatrics*, **2020**, 224, 44-50.e1 | 3.6 | 4 |
| 91 | The future of cystic fibrosis care: a global perspective. *Lancet Respiratory Medicine,the*, **2020**, 8, 65-124 | 35.1 | 259 |
| 90 | Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. *Physiological Genomics*, **2019**, 51, 27-41 | 3.6 | 8 |
| 89 | Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis. *Journal of Cystic Fibrosis*, **2018**, 17, 528-535 | 4.1 | 23 |
| 88 | Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. *European Journal of Human Genetics*, **2018**, 26, 1832-1839 | 5.3 | 35 |
| 87 | Quantitative chest computerized tomography and FEV equally identify pulmonary exacerbation risk in children with cystic fibrosis. *Pediatric Pulmonology*, **2018**, 53, 1369-1377 | 3.5 | 5 |
| 86 | Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses. *Journal of Pediatrics*, **2017**, 181S, S27-S32.e1 | 3.6 | 43 |
| 85 | Diagnosis of Cystic Fibrosis in Nonscreened Populations. *Journal of Pediatrics*, **2017**, 181S, S52-S57.e2 | 3.6 | 37 |

| | | | |
|---|---|---|---|
| 84 | Introduction to "Cystic Fibrosis Foundation Consensus Guidelines for Diagnosis of Cystic Fibrosis". *Journal of Pediatrics*, **2017**, 181S, S1-S3 | 3.6 | 3 |
| 83 | Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. *Journal of Pediatrics*, **2017**, 181S, S4-S15.e1 | 3.6 | 368 |
| 82 | Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. *Journal of Pediatrics*, **2017**, 181S, S16-S26 | 3.6 | 21 |
| 81 | Diagnosis of Cystic Fibrosis in Screened Populations. *Journal of Pediatrics*, **2017**, 181S, S33-S44.e2 | 3.6 | 60 |
| 80 | Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV decline. *Journal of Cystic Fibrosis*, **2017**, | 4.1 | 2 |
| 79 | Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes. *Pediatric Pulmonology*, **2017**, 52, 1268-1275 | 3.5 | 11 |
| 78 | The Evolution of the Medical School Deanship: From Patriarch to CEO to System Dean **2017**, 21, 16-069 | | 3 |
| 77 | Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis. *Pediatric Pulmonology*, **2016**, 51, 1295-1303 | 3.5 | 6 |
| 76 | Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. *Genetics in Medicine*, **2016**, 18, 231-8 | 8.1 | 54 |
| 75 | Access to Primary Care and Subspecialty Care After Positive Cystic Fibrosis Newborn Screening. *Wisconsin Medical Journal*, **2016**, 115, 295-9 | 0.5 | |
| 74 | Changing incidence of cystic fibrosis in Wisconsin, USA. *Pediatric Pulmonology*, **2015**, 50, 1065-1072 | 3.5 | 10 |
| 73 | Challenges in Cystic Fibrosis Newborn Screening and Recommendations for Primary Care Physicians. *Pediatrics*, **2015**, 136, 1181-4 | 7.4 | 3 |
| 72 | Improving the quality of physician communication with rapid-throughput analysis and report cards. *Patient Education and Counseling*, **2014**, 97, 248-55 | 3.1 | 12 |
| 71 | Risk factors for the progression of cystic fibrosis lung disease throughout childhood. *Annals of the American Thoracic Society*, **2014**, 11, 63-72 | 4.7 | 47 |
| 70 | Long-term follow-up of cystic fibrosis newborn screening: psychosocial functioning of adolescents and young adults. *Journal of Cystic Fibrosis*, **2014**, 13, 227-34 | 4.1 | 13 |
| 69 | WisconsinS Lifecourse Initiative for Healthy Families: application of the maternal and child health life course perspective through a regional funding initiative. *Maternal and Child Health Journal*, **2014**, 18, 413-22 | 2.4 | 8 |
| 68 | Effects of immediate telephone follow-up with providers on sweat chloride test timing after cystic fibrosis newborn screening identifies a single mutation. *Journal of Pediatrics*, **2013**, 162, 522-9 | 3.6 | 5 |
| 67 | Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. *Journal of Cystic Fibrosis*, **2012**, 11, 150-3 | 4.1 | 17 |

| | | | |
|---|---|---|---|
| 66 | Estimating the annual number of false negative cystic fibrosis newborn screening tests. *Pediatric Pulmonology*, **2012**, 47, 207-8 | 3.5 | 10 |
| 65 | A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. *Pediatrics*, **2012**, 129, e339-47 | 7.4 | 30 |
| 64 | Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. *Journal of Cystic Fibrosis*, **2011**, 10, 278-81 | 4.1 | 30 |
| 63 | Associations between academic achievement and psychosocial variables in adolescents with cystic fibrosis. *Journal of School Health*, **2011**, 81, 713-20 | 2.1 | 16 |
| 62 | Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. *Pediatric Pulmonology*, **2011**, 46, 1166-74 | 3.5 | 23 |
| 61 | Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. *Chest*, **2011**, 140, 170-177 | 5.3 | 20 |
| 60 | Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. *Pediatrics*, **2009**, 123, e338-46 | 7.4 | 41 |
| 59 | Recovery of birth weight z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fibrosis. *Pediatrics*, **2009**, 123, 714-22 | 7.4 | 74 |
| 58 | Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *Journal of Pediatrics*, **2009**, 155, S73-93 | 3.6 | 257 |
| 57 | Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. *Journal of Pediatrics*, **2009**, 155, S106-16 | 3.6 | 123 |
| 56 | European best practice guidelines for cystic fibrosis neonatal screening. *Journal of Cystic Fibrosis*, **2009**, 8, 153-73 | 4.1 | 155 |
| 55 | Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. *Radiology*, **2009**, 252, 534-43 | 20.5 | 45 |
| 54 | Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *Journal of Pediatrics*, **2008**, 153, S4-S14 | 3.6 | 731 |
| 53 | Is newborn screening for cystic fibrosis a basic human right?. *Journal of Cystic Fibrosis*, **2008**, 7, 262-5 | 4.1 | 8 |
| 52 | The prevalence of cystic fibrosis in the European Union. *Journal of Cystic Fibrosis*, **2008**, 7, 450-3 | 4.1 | 260 |
| 51 | Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. *Pediatrics*, **2007**, 119, e495-518 | 7.4 | 99 |
| 50 | The meaning of "early" diagnosis in a new era of cystic fibrosis care. *Pediatrics*, **2007**, 119, 156-7 | 7.4 | 51 |
| 49 | Cystic fibrosis mutations and genotype-pulmonary phenotype analysis. *Journal of Cystic Fibrosis*, **2006**, 5, 33-41 | 4.1 | 23 |

| | | | |
|---|---|---|---|
| 48 | Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. *Journal of Pediatrics*, **2006**, 149, 362-6 | 3.6 | 80 |
| 47 | Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. *Journal of Thoracic Imaging*, **2006**, 21, 14-21 | 5.6 | 120 |
| 46 | Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. *Journal of Pediatrics*, **2005**, 147, S30-6 | 3.6 | 113 |
| 45 | Assessing the cost of cystic fibrosis diagnosis and treatment. *Journal of Pediatrics*, **2005**, 147, S101-5 | 3.6 | 16 |
| 44 | Plan to address physician shortage requires proper support. *Wisconsin Medical Journal*, **2005**, 104, 73-4 | 0.5 | |
| 43 | Cystic fibrosis newborn screening: shifting the key question from "should we screen?" to "how should we screen?". *Pediatrics*, **2004**, 113, 1811-2 | 7.4 | 12 |
| 42 | Longitudinal pulmonary status of cystic fibrosis children with meconium ileus. *Pediatric Pulmonology*, **2004**, 38, 277-84 | 3.5 | 36 |
| 41 | Welcoming incremental, measurable change. *Wisconsin Medical Journal*, **2004**, 103, 67-8 | 0.5 | |
| 40 | Using science to improve health care delivery and patient care. *Wisconsin Medical Journal*, **2004**, 103, 87-8 | 0.5 | |
| 39 | Excellent progress has been made but significant challenges remain. *Wisconsin Medical Journal*, **2004**, 103, 91-2 | 0.5 | |
| 38 | Celebrating the importance of medical history. *Wisconsin Medical Journal*, **2004**, 103, 76 | 0.5 | |
| 37 | Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 1100-8 | 10.2 | 107 |
| 36 | Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. *Pediatric Pulmonology*, **2003**, 36, 230-40 | 3.5 | 74 |
| 35 | Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. *Journal of Pediatrics*, **2003**, 142, 617-23 | 3.6 | 42 |
| 34 | New research, perspectives required to understand impact of gender on health. *Wisconsin Medical Journal*, **2003**, 102, 57-8 | 0.5 | |
| 33 | Using the power of genetics, genomics and molecular biology to fight cancer. *Wisconsin Medical Journal*, **2003**, 102, 51-2 | 0.5 | |
| 32 | A fruitful and gratifying collaboration. *Wisconsin Medical Journal*, **2003**, 102, 89-90 | 0.5 | |
| 31 | Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. *Human Mutation*, **2002**, 19, 575-606 | 4.7 | 765 |

| | | | |
|---|---|---|---|
| 30 | Delayed diagnosis of US females with cystic fibrosis. *American Journal of Epidemiology*, **2002**, 156, 165-73 | 3.8 | 49 |
| 29 | Prenatal screening for cystic fibrosis: where are we now?. *Journal of Pediatrics*, **2002**, 141, 758-63 | 3.6 | 16 |
| 28 | Preparing for bioterrorism. *Wisconsin Medical Journal*, **2002**, 101, 35-6 | 0.5 | |
| 27 | Enhancing men's urologic health. *Wisconsin Medical Journal*, **2002**, 101, 46-7 | 0.5 | |
| 26 | Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. *Pediatrics*, **2001**, 107, 699-705 | 7.4 | 114 |
| 25 | Genetic counseling and risk communication services of newborn screening programs. *JAMA Pediatrics*, **2001**, 155, 120-6 | | 55 |
| 24 | Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition **2001**, 32, 277 | | 11 |
| 23 | Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies. *Pediatric Pulmonology*, **2000**, 29, 457-67 | 3.5 | 42 |
| 22 | Nutritional status of patients with cystic fibrosis with meconium ileus: a comparison with patients without meconium ileus and diagnosed early through neonatal screening. *Pediatrics*, **2000**, 105, 53-61 | 7.4 | 86 |
| 21 | Comparison of growth status of patients with cystic fibrosis between the United States and Canada. *American Journal of Clinical Nutrition*, **1999**, 69, 531-8 | 7 | 67 |
| 20 | Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis. *Pediatric Pulmonology*, **1998**, 26, 81-8 | 3.5 | 79 |
| 19 | Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. *Pediatrics*, **1998**, 102, 44-52 | 7.4 | 115 |
| 18 | Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. *New England Journal of Medicine*, **1997**, 337, 963-9 | 59.2 | 307 |
| 17 | The incidence of cystic fibrosis. *Statistics in Medicine*, **1996**, 15, 449-62 | 2.3 | 88 |
| 16 | THE INCIDENCE OF CYSTIC FIBROSIS **1996**, 15, 449 | | 1 |
| 15 | Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. *Clinical Pediatrics*, **1994**, 33, 2-7 | 1.2 | 48 |
| 14 | Progressive malnutrition, severe anemia, hepatic dysfunction, and respiratory failure in a three-month-old white girl. *American Journal of Medical Genetics Part A*, **1993**, 45, 725-38 | | 11 |
| 13 | Nutritional assessment of infants with cystic fibrosis diagnosed through screening. *Pediatric Pulmonology*, **1991**, 7, 56-63 | 3.5 | 18 |

| | | | |
|---|---|---|---|
| 12 | Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. *Pediatric Pulmonology*, **1991**, 7, 76-83 | 3.5 | 9 |
| 11 | Newborn Screening for Cystic Fibrosis Is Complicated by Age-Related Decline in Immunoreactive Trypsinogen Levels. *Pediatrics*, **1990**, 85, 1001-1007 | 7.4 | 25 |
| 10 | Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. *Pediatric Pulmonology*, **1989**, 6, 42-8 | 3.5 | 61 |
| 9 | Correction of linoleic acid deficiency in cystic fibrosis. *Pediatric Research*, **1986**, 20, 36-41 | 3.2 | 50 |
| 8 | A case report and literature review of "primary" pulmonary histiocytosis X of childhood. *Medical and Pediatric Oncology*, **1986**, 14, 57-62 | | 25 |
| 7 | Changes in surfactant phospholipids in fetal rat lungs from normal and diabetic pregnancies. *Pediatric Research*, **1986**, 20, 650-4 | 3.2 | 20 |
| 6 | Effect of choline deficiency on lung phospholipid concentrations in the rat. *Journal of Nutrition*, **1986**, 116, 936-43 | 4.1 | 5 |
| 5 | Fatty acid abnormalities in cystic fibrosis. *Pediatric Research*, **1985**, 19, 104-9 | 3.2 | 135 |
| 4 | Tocopherol isomers in intravenous lipid emulsions and resultant plasma concentrations. *Journal of Parenteral and Enteral Nutrition*, **1984**, 8, 269-73 | 4.2 | 29 |
| 3 | Early Diagnosis of Cystic Fibrosis: To Screen or Not To Screen An Important Question. *Pediatrics*, **1984**, 73, 115-117 | 7.4 | 1 |
| 2 | Evaluation of vitamin E deficiency in children with lung disease. *Annals of the New York Academy of Sciences*, **1982**, 393, 96-108 | 6.5 | 21 |
| 1 | The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. *Journal of Clinical Investigation*, **1977**, 60, 233-41 | 15.9 | 189 |